




2023 Society of Toxicology/Poster #3046/P148

A Naturally Occurring Novel Therapeutic and Oral Selective Inhibitor of TNF- α , MYMD-1[®] (*Isomyosamine*) Significantly Reduced the Inflammation and Disease Severity in Murine Model of Collagen Antibody-Induced Arthritis



Statistical analyses were performed using Unpaired student t-test, One-Way or Two-way ANOVA in comparison to the CAIA/vehicle control. *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$; ****: $p < 0.0001$.

Composite Score is the severity and sum of all histopathology parameters listed below from the results of the study.

Disease severity (total composite score) was reduced by 47% with MYMD-1[®] at 450 mg/kg/day orally versus a 37% reduction for etanercept 10 mg/kg by subcutaneous injection (see graph above).

Bone Resorption is found in areas in which osteoclasts are actively removing bone and bone loss occurs.

Periosteal and exostotic changes are found in areas in which a periosteal reaction occurs. The periosteum is active and is thickened by woven or mature bone formation.

Pannus and synovial hyperplasia occur when the synoviocytes are plump and/or increased in number. Pannus is a fibrovascular tissue, which corresponds to vascular granulation tissue.

MYMD-1[®] reduction in the severity of the combined histopathology disease results were better than etanercept by ten percentage points.